iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings, Inc. ownership disclosure: RTW Investments, LP and Roderick Wong report beneficial ownership of 1,668,500 shares of Common Stock, representing 5.2% of the class. The filing cites 32,316,760 Shares outstanding as of February 12, 2026. The statement is signed by Dr. Wong on May 15, 2026.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar reported option exercises and offsetting share sales under a pre-set trading plan. On May 11, 2026, he exercised 5,312 Employee Stock Options at $10.71 per share and acquired the same number of common shares.
That same day he sold an aggregate of 5,312 common shares in multiple open‑market transactions at prices ranging from about $115.61 to $120.53, resulting in no net change in his common stock holdings. After these transactions, he directly owned 25,611 common shares. All trades were executed pursuant to a Rule 10b5-1 trading plan established on May 12, 2025.
IRTC disclosed a proposed sale of 5,312 shares of Common Stock through a stock option exercise to be effected on 05/11/2026 with cash as the consideration. The filing lists $773,981.24 tied to securities sold in the past three months and attributes the transaction to an issuer-directed exercise.
iRhythm Holdings, Inc. - Sands Capital Management, LLC and Frank M. Sands filed Amendment No. 6 to a Schedule 13G/A reporting beneficial ownership of 5% or less of the issuer's common stock (CUSIP 450056106). The filing states securities are held in various client accounts and that no single client's interest exceeds 5%.
The filing cites 32,862,408 shares outstanding as of April 23, 2026 (per the issuer's Form 10-Q). Sands is identified as having ultimate voting and investment power over securities held by Sands Capital. Signatures are dated 05/08/2026.
iRhythm Holdings, Inc. Chief Technology Officer Lawrence Brian Lee reported a small share disposition linked to equity compensation. On this Form 4, he sold 1,014 shares of common stock at $120.80 per share, and held 20,154 shares afterward.
According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units (RSUs), indicating a routine, compensation-related transaction rather than a discretionary open-market sale for portfolio reasons.
iRhythm Holdings, Inc. reported higher Q1 2026 revenue but remained unprofitable. Revenue rose to $199.4 million, up from $158.7 million a year earlier, driven mainly by contracted commercial payors and Medicare. Net loss narrowed to $13.9 million, or $0.43 per share, compared with a $30.7 million loss, reflecting improved operating leverage.
The company ended the quarter with $240.1 million in cash and cash equivalents and $309.5 million in marketable securities, against $661.3 million of 1.50% senior convertible notes due 2029. Adjusted EBITDA turned positive at $14.1 million versus a negative $2.6 million a year earlier.
iRhythm continues to invest in internal-use software, strategic investments (including loans to BioIntelliSense), and stock-based compensation, while managing credit losses and contractual allowances on receivables. The company also discloses ongoing securities, patent, and government matters and states it is cooperating with authorities and defending these cases.
iRhythm Holdings reported strong first quarter 2026 results with revenue of $199.4 million, up 25.7% from $158.7 million a year earlier, driven by higher Zio service volumes and newer growth channels.
Gross profit rose to $141.4 million with gross margin improving to 70.9%, while operating expenses increased to $157.5 million as the company invested in growth and incurred litigation-related costs. Net loss narrowed to $13.9 million, or $0.43 per share, from $30.7 million, helped by operating leverage and non-GAAP adjustments that lifted adjusted EBITDA to $14.1 million.
Unrestricted cash, cash equivalents, and marketable securities totaled $549.6 million as of March 31, 2026, and the company raised full-year 2026 guidance to revenue of $875–$885 million with an adjusted EBITDA margin of 12%–13%, reflecting expectations for continued volume-led growth and margin expansion.
Vanguard Portfolio Management reports beneficial ownership of 1,824,090 shares of IRhythm Holdings Inc. The filing states this equals 5.64% of the class as of 03/31/2026, with Vanguard holding sole dispositive power for all 1,824,090 shares and sole voting power for 27,718 shares.
Vanguard Capital Management reported beneficial ownership of 1,691,483 shares of IRhythm Holdings Inc. common stock, equal to 5.23% of the class. The filer reports sole voting power over 245,773 shares and sole dispositive power over 1,691,483 shares. The filing is signed by Ashley Grim on 04/27/2026.
iRhythm Holdings, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on May 27, 2026, including the election of nine directors and several key governance and compensation items.
The company seeks approval of a new 2026 Equity Incentive Plan reserving 1,690,000 shares, which will succeed its 2016 plan, plus ratification of KPMG as auditor, an advisory say-on-pay vote, and an amended and restated certificate of incorporation for subsidiary iRhythm Technologies, Inc. to remove a pass-through voting provision.
iRhythm highlights 2025 performance, including revenue of $747.1 million, 26.2% year-over-year growth, first-ever positive quarterly GAAP net income, first full year of positive free cash flow, adjusted EBITDA of $68.9 million (9.2% of revenue), and year-end cash, cash equivalents and marketable securities of $583.8 million.
The proxy also emphasizes an independent, skills-diverse board, robust risk oversight (including AI and cybersecurity), and sustainability efforts such as a 92.3% landfill waste diversion rate and completion of a Scope 3 greenhouse gas emissions inventory.